Salk Institute-led work introduced Superb-seq, a single-cell platform designed to capture both Cas9 edit presence and transcriptome changes, addressing a key gap in understanding how on-target and off-target edits translate into gene-expression effects. The method integrates Cas9 editing readouts with single-cell RNA sequencing, enabling mapping of unwanted edits and their downstream biological impact. In reported tests across multiple cell lines, Superb-seq detected edit sites at high frequency and identified off-target sites that existing detection strategies might miss, with corresponding gene-expression perturbations. The authors argue this improves interpretability compared with approaches that capture guide sequences and expression but do not directly reveal edit locations. For the CRISPR therapeutic space, single-cell edit readouts can strengthen candidate selection and safety evaluation by connecting genomic edit patterns to functional outcomes before clinical translation.